Evaluation of injectable CaHA for the treatment of mid-face volume loss.
BACKGROUND
Calcium hydroxylapatite (CaHA) is presently approved for the correction of moderate to severe facial wrinkles and folds and signs of HIV-associated facial lipoatrophy.


OBJECTIVE
This 6-month pilot study was designed to evaluate clinical efficacy and patient satisfaction of CaHA to treat mid-face volume loss.


METHODS
Nineteen patients received initial malar injections of CaHA. At 1, 3, and 6 months, patients were evaluated for mid-face volume loss, satisfaction, and adverse events. Touch ups were administered at 3 months, with enhancement injections permitted at 6 months.


RESULTS
Average treatment volumes were 1.3 mL CaHA gel per side. At 1, 3, and 6 months, 88%, 74%, and 75% of patients rated themselves "very satisfied/satisfied" and physicians rated 82%, 100%, and 94% of patients as "im proved" or greater, respectively. Global Aesthetic Improvement Scale (GAIS) scores were similar. At 6 months, 88% of patients were pleased with the outcome and 81% would recommend CaHA cheek augmentation.


CONCLUSIONS
Malar augmentation with CaHA gel appears to be a viable nonsurgical alternative for patients with mid-face volume loss, with good patient satisfaction and excellent tolerability.
Beer
Kenneth
K
Palm Beach Esthetic Center, West Palm Beach, FL 33401, USA. kenbeer@aol.com
Yohn
Monica
M
Cohen
Joel L
JL
D000328:Adult; D000368:Aged; D015992:Body Mass Index; D002610:Cheek; D003357:Cosmetic Techniques; D017886:Durapatite / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005782:Gels; D039682:HIV-Associated Lipodystrophy Syndrome / Q000628:therapy*; D006801:Humans; D007271:Injections, Intradermal; D008875:Middle Aged; D017060:Patient Satisfaction; D010865:Pilot Projects; D012060:Rejuvenation
D005782:Gels; D017886:Durapatite